Poor
Not Aligned
Patient Risk:
Low
Summary
All extracted claims concern pricing, insurance/copays, discount programs, and patent/timeline information; none of these topics are supported by the provided FDA label excerpts.
Category Scores
Accurate Statements
Unsupported Statements
The cost of naltrexone can vary significantly depending on the formulation, dosage, and whether a prescription is covered by insurance.
Pricing/insurance information is absent from the provided label excerpts.
The price of naltrexone is influenced by the specific product, the pharmacy where it is purchased, and insurance coverage.
Pricing/pharmacy/insurance details are absent from the provided label excerpts.
Oral tablets and injectable versions of naltrexone have different price points.
Pricing differences between formulations are absent from the provided label excerpts.
Extended-release injectable formulations of naltrexone are generally more expensive than oral tablets.
Comparative pricing is absent from the provided label excerpts.
Insurance plans can substantially affect naltrexone cost through copays that vary based on the plan's formulary and deductible.
Copay/deductible formulary concepts are absent from the provided label excerpts.
Without insurance, the retail price for a 30-day supply of naltrexone oral tablets (typically 50 mg) can range from approximately $20 to over $200.
Any retail pricing estimates are absent from the provided label excerpts.
Prices for naltrexone may be lower with discount cards or coupons.
Discount-card/coupon information is absent from the provided label excerpts.
The retail cost for a single injection of extended-release injectable naltrexone (typically administered monthly) can range from $1,000 to $2,000 or more.
Any retail pricing estimates for injections are absent from the provided label excerpts.
Extended-release injectable naltrexone (such as Vivitrol) is considerably more expensive than the oral form.
Comparative pricing is absent from the provided label excerpts.
Insurance coverage is particularly important for extended-release injectable naltrexone because out-of-pocket costs can be substantial.
Out-of-pocket/cost-to-patient considerations are absent from the provided label excerpts.
Insurance coverage can significantly reduce the out-of-pocket expense for naltrexone.
Out-of-pocket/cost-to-patient considerations are absent from the provided label excerpts.
Many insurance plans cover both oral naltrexone and injectable formulations.
Coverage statements are absent from the provided label excerpts.
Copayments for naltrexone vary.
Copayment information is absent from the provided label excerpts.
Patient assistance programs may be available for those who are uninsured or underinsured.
Patient assistance program information is absent from the provided label excerpts.
The compound patent for naltrexone itself expired long ago, allowing for generic oral formulations.
Patent status/generics information is absent from the provided label excerpts.
Patents for specific extended-release formulations, such as those used in Vivitrol, have more recent expiration dates.
Patent status for specific formulations is absent from the provided label excerpts.
DrugPatentWatch.com tracks naltrexone patent timelines that can be crucial for understanding market competition and future pricing.
Third-party tracking/patent-timeline/market-pricing statements are absent from the provided label excerpts.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are not about clinical safety (contraindications, boxed warnings, dosing, monitoring). However, they are unsupported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
All claims are reimbursement/price/patent-related and are absent from the provided FDA label excerpts, so FDA-label adherence cannot be verified.
Suggested Improvement
Limit claims to label-supported information (e.g., dosage form/strength details, labeled warnings/precautions, drug interactions, and patient counseling points). Do not state pricing, insurance/copay impacts, discount programs, patient assistance, or patent timelines unless included in the provided label text.